Dose-escalation models for combination phase I trials in oncology.
about
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeTwo drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyOpportunities and challenges in the development of experimental drug combinations for cancer.American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?Dose-toxicity models in oncology.The changing landscape of phase I trials in oncology.Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.A two-dimensional biased coin design for dual-agent dose-finding trials.Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.Design considerations for dose-expansion cohorts in phase I trialsEscalation strategies for combination therapy Phase I trials.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.A two-dimensional search algorithm for dose-finding trials of two agents.
P2860
Q26830525-0D8B225F-4336-42C3-815D-6F7FFB9D0D75Q26996348-8D52C755-6B7D-450A-83B6-1999E7F05102Q34001009-42072651-DCEA-4AF7-9F2F-C02522040BA0Q34056295-4BE72821-3194-4940-AEB1-7ED267A569B6Q34795914-00F12969-5F5E-4263-B2A6-9B6278315E7DQ35074974-7989F42E-B776-4CC6-97BF-12F98D98B696Q35555293-8D86CF2C-06DD-454A-AC91-53358D932228Q35894574-B2F18E7A-EDFF-4B6B-8276-F31E3209F325Q36295897-6959C1AC-EABE-47C5-8B42-661A14870166Q37129865-F1DE0BE9-E9F0-4F3F-A563-973C08AF1151Q37829437-6CE66465-6D0B-429E-BCA2-57217AA037D4Q38629203-32F5F259-7EE5-4C84-B274-983F0A62C04CQ38733577-1B6CA030-EDDA-4D32-9C09-19A7E4363675Q40749503-A514C289-D3EA-4D7D-AA39-810A16BB1ACCQ41658065-1C68A2F3-5B4C-4AE7-8CAE-866EB73D18E1Q41673963-BA985E9D-2D2B-49DF-B1E2-B39381EACE81Q41895594-74721303-79F9-4310-8010-67C6ABF481C5Q43246672-BAE6CF29-DA69-424F-B9F2-60468D75EF51Q44209463-0C7DC4A3-8FE8-4286-B8B4-7257130FC890Q45994683-DC3422C2-38C4-481C-962C-EFB8C1207A76Q45994896-FE8D0B8C-65CA-4030-8733-BE75F51DFD41Q51360446-45405024-FAF1-4B3E-8C39-0D754A7F5608
P2860
Dose-escalation models for combination phase I trials in oncology.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dose-escalation models for combination phase I trials in oncology.
@ast
Dose-escalation models for combination phase I trials in oncology.
@en
type
label
Dose-escalation models for combination phase I trials in oncology.
@ast
Dose-escalation models for combination phase I trials in oncology.
@en
prefLabel
Dose-escalation models for combination phase I trials in oncology.
@ast
Dose-escalation models for combination phase I trials in oncology.
@en
P1476
Dose-escalation models for combination phase I trials in oncology.
@en
P2093
Jaap Verweij
Paul Hamberg
P304
P356
10.1016/J.EJCA.2010.07.002
P577
2010-08-04T00:00:00Z